Holen Sie sich die Stockscreener-App
59.67
2.65%
-1.625
Handel nachbörslich:
59.30
-0.375
-0.63%
Schlusskurs vom Vortag:
$61.30
Offen:
$60.99
24-Stunden-Volumen:
132.21K
Relative Volume:
2.98
Marktkapitalisierung:
$1.90B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.61M
KGV:
-50.82
EPS:
-1.1742
Netto-Cashflow:
-
1W Leistung:
-5.76%
1M Leistung:
-1.33%
6M Leistung:
+1.30%
1J Leistung:
+19.52%
1-Tages-Spanne:
$59.12
$62.64
1-Wochen-Bereich:
$59.12
$63.30
52-Wochen-Spanne:
$43.70
$86.53
Belite Bio Inc Adr Stock (BLTE) Company Profile
Firmenname
Belite Bio Inc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BLTE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
59.67 | 2.06B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-14 | Eingeleitet | Maxim Group | Buy |
| 2023-07-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Eingeleitet | SVB Securities | Outperform |
| 2022-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-01 | Eingeleitet | The Benchmark Company | Buy |
Belite Bio Inc Adr Aktie (BLTE) Neueste Nachrichten
New Strong Sell Stocks For July 22nd - Barchart.com
What analysts say about Belite Bio Inc Depositary Receipt stockConsistent wealth multiplication - jammulinksnews.com
Belite Bio concludes enrollment for phase 3 GA trial on oral tinlarebant - Eyes On Eyecare
Stargardt Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Solid Biosciences (SLDB) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
Q2 EPS Estimates for Belite Bio Decreased by Leerink Partnrs - Defense World
Ouster Announces Date for Second Quarter 2025 Earnings Call - The Globe and Mail
Belite Bio, Inc.’s Tinlarebant: Promising Treatment for Stargardt Disease with Significant Market Potential - TipRanks
Phase 3 PHOENIX trial for oral GA treatment completes enrollment - Modern Retina
Belite Bio stock maintains Buy rating at H.C. Wainwright on trial progress - Investing.com India
Belite Bio Completes Enrollment for Phase 3 PHOENIX Trial on Tinlarebant - TipRanks
Positive Buy Rating for Belite Bio Driven by Phase 3 PHOENIX Trial Milestone and Regulatory Designations - TipRanks
Analysts Issue Forecasts for Belite Bio FY2026 Earnings - Defense World
Reviewing Belite Bio (NASDAQ:BLTE) & ZyVersa Therapeutics (NASDAQ:ZVSA) - Defense World
Bank of America Corp DE Acquires 4,891 Shares of Belite Bio, Inc (NASDAQ:BLTE) - Defense World
Cohen & Company Inc. (NYSEAMERICAN:COHN) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Belite Bio, Inc (NASDAQ:BLTE) Shares Sold by Citadel Advisors LLC - Defense World
BNP Paribas Financial Markets Acquires New Shares in Belite Bio, Inc (NASDAQ:BLTE) - Defense World
What is HC Wainwright’s Forecast for Belite Bio Q1 Earnings? - Defense World
What is HC Wainwright's Estimate for Belite Bio Q2 Earnings? - MarketBeat
Belite Bio stock holds $80 target on FDA breakthrough nod By Investing.com - Investing.com Nigeria
Belite Bio stock holds $80 target on FDA breakthrough nod - Investing.com
Belite Bio’s Promising Outlook: FDA Breakthrough Designation and Upcoming Milestones Boost Buy Rating - TipRanks
Yi Chen Recommends Buy Rating for Belite Bio Due to Breakthrough Therapy Designation and Promising Trial Progress - TipRanks
Why Belite Bio’s Stock is Soaring High - TipRanks
Belite Bio’s Tinlarebant Receives FDA Breakthrough Therapy Designation for Stargardt Disease - TipRanks
Belite Bio Says FDA Grants Breakthrough Therapy Tag to Stargardt Disease Drug - marketscreener.com
Belite Bio Announces FDA Granting Of Breakthrough Therapy Designation For Tinlarebant For The Treatment Of Stargardt Disease - marketscreener.com
Belite Bio Receives FDA Breakthrough Therapy Designation for Tinlarebant in Treating Stargardt Disease - Nasdaq
Belite Bio Announces FDA Granting of Breakthrough Therapy - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Arcellx Inc (ACLX) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
Q2 Earnings Estimate for Belite Bio Issued By HC Wainwright - Defense World
Belite Bio (NASDAQ:BLTE) Earns “Overweight” Rating from Cantor Fitzgerald - Defense World
HC Wainwright Reaffirms Buy Rating for Belite Bio (NASDAQ:BLTE) - Defense World
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - GlobeNewswire
Benchmark maintains Buy on Belite Bio stock, $80 price target unchanged - Investing.com Nigeria
Belite Bio’s Earnings Call Highlights Clinical Progress and Financial Strength - TipRanks
Belite Bio at Deutsche Bank Conference: Promising Drug Trials By Investing.com - Investing.com India
Transcript : Belite Bio, Inc Presents at Deutsche Bank ADR Virtual Investor Conference, May-15-2025 12 - marketscreener.com
Belite Bio at Deutsche Bank Conference: Promising Drug Trials - Investing.com
Belite Bio stock retains Overweight rating at Cantor Fitzgerald - Investing.com Australia
Belite Bio stock retains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com India
Promising Clinical Trials and Strategic Developments Justify Buy Rating for Belite Bio - TipRanks
Belite Bio Advances Clinical Trials Amid Financial Challenges - TipRanks
Earnings call transcript: Belite Bio’s Q1 2025 sees narrower EPS loss - Investing.com Nigeria
Earnings Flash (BLTE) Belite Bio Q1 Loss $0.45 Vs. FactSet Est. $0.35 Loss - marketscreener.com
Belite Bio Q1 2025 Earnings Call Transcript - MarketBeat
Belite Bio Advances Tinlarebant Trials with Positive Interim Results - TipRanks
Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - ADVFN
Belite Bio reports Q1 EPS (45c), consensus (37c) - TipRanks
Finanzdaten der Belite Bio Inc Adr-Aktie (BLTE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):